"Welcome to the Piedmont Cancer Institute (“PCI”) - not just a place, but your care partner. At PCI our physicians and staff seek to understand and treat the whole patient. When faced with the fact that the word “cancer” has entered the life of a patient and their family, a flood of images and emotions present themselves. At PCI, we see each patient as an individual and each circumstance is unique. When you choose PCI as your partner in your cancer journey, you can expect the best possible care, using leading-edge cancer therapies, participation in clinical trials accessing newly developed cancer treatments and the extensive resources of the Piedmont Cancer Center and its comprehensive cancer treatment team."

During the past decade, Piedmont Cancer Institute, PC conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Piedmont Cancer Institute, PC" #1 collaborator was "Cancer Research UK" with 2 trials as a collaborator, "Destroy Pancreatic Cancer" with 2 trials as a collaborator, "Lustgarten Foundation" with 2 trials as a collaborator, "Stand Up To Cancer" with 2 trials as a collaborator and "Translational Genomics Research Institute" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Piedmont Cancer Institute, PC" are "Metastatic Pancreatic Cancer" (2 trials), "Metastatic Breast Cancer" (1 trials), "Pancreas Cancer" (1 trials), "Pancreatic Adenocarcinoma Resectable" (1 trials) and "Pancreatic Cancer" (1 trials). Many other conditions were trialed in "Piedmont Cancer Institute, PC" in a lesser frequency.

Most popular intervention types in "Piedmont Cancer Institute, PC" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Ascorbic Acid" (2 trials), "Cisplatin" (2 trials), "Gemcitabine" (2 trials), "Fulvestrant" (1 trials) and "Paclitaxel protein-bound" (1 trials). Other intervention names were less common.

The vast majority of trials in "Piedmont Cancer Institute, PC" are 2 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Piedmont Cancer Institute, PC". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Piedmont Cancer Institute, PC, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Piedmont Cancer Institute, PC, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".